CureVac´s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate
- CureVac’s mRNA platform demonstrated positive low dose results in multiple indications including Flu, RSV and in humans for Rabies
- Coronavirus lead vaccine candidate has generated high levels of virus neutralizing titers after two 2 microgram dose vaccinations in pre-clinical experiments
- GMP manufacturing of large quantities of drug-substance completed
CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2). The data showed a fast induction of a balanced immune response with high levels of virus neutralizing titers (VNTs) and T-cell responses. VNTs are a major criterion supporting that the vaccine candidate has the potential to induce a strong immunologic response to neutralize SARS-CoV-2.